Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
Corporate Governance
Resources

News Releases

Year

Jun 12 / 26

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Jun 02 / 26

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 20 / 26

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

May 18 / 26

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

May 15 / 26

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

May 13 / 26

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

Apr 27 / 26

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

Apr 23 / 26

Belite Bio to Participate in Four Upcoming Investor Conferences

Apr 21 / 26

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 9 of 15

Belite Bio™ Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio